Tal Kafri

Tal Kafri, MD, PhD, is a Professor of Microbiology and Immunology at the University of North Carolina at Chapel Hill School of Medicine and a member of the UNC Lineberger Comprehensive Cancer Center. He serves as Director of both the Lenti Viral Vector Core and Lenti-shRNA Core Facility within the Gene Therapy Center, where he leads a comprehensive research program focused on lentiviral vector development for therapeutic applications.

Dr. Kafri's research spans multiple critical areas in gene therapy and virology, with primary emphasis on HIV-1 vector systems. His laboratory investigates lentiviral vector production, transgene expression regulation, vector biosafety, and animal models for testing vector efficacy. Specific research interests include developing integration-deficient vectors to minimize insertional mutagenesis risks, creating inducible packaging cell lines for large-scale vector production, and studying the mechanisms of HIV-1 biology including viral latency and non-integrated genome expression. His work has significant applications for treating genetic disorders like hemophilia and Krabbe disease, as well as acquired conditions including prostate cancer.

Analysis of Dr. Kafri's publication record reveals a consistent research trajectory focused on improving lentiviral vector safety and efficacy. His recent work has expanded into novel applications including cancer immunotherapy using mast cells, Alzheimer's disease research, and retinal disease treatment. The publications demonstrate expertise spanning basic virology, vector engineering, and translational applications, with particular strength in understanding the molecular mechanisms that govern viral vector integration, transgene expression, and host-virus interactions.

Dr. Kafri leads the Kafri Lab, which includes multiple research associates, technicians, and core facility managers working collaboratively on vector development projects. The laboratory maintains strong connections with other research groups within the Gene Therapy Center, including collaborations with the Fu Lab, Hirsch Lab, Li Lab, McCown Lab, and Samulski Lab. His team utilizes sophisticated animal models including hemophilic mice and canines to evaluate vector safety and efficacy, bridging basic science with potential clinical applications.